Orris

gene therapy in cystic fibrosis

Reading File
Finding Sources
Searching PubMed

"cystic fibrosis"[MeSH Terms] AND "gene therapy"[MeSH Terms]

Searching the Web

gene therapy cystic fibrosis 2025 2026 clinical trials CFTR

Finding Sources
Searching PubMed

"cystic fibrosis" AND "mRNA therapy" OR "gene editing" OR "CRISPR"

Reading Web Page

https://cysticfibrosisnewstoday.com/news/new-ucla-research-s…

Finding Sources
Searching PubMed

"cystic fibrosis" AND ("gene therapy" OR "mRNA therapy" OR "CRISPR") AND "airway"

Reading Article

PMID: 39439894

Finding Sources
Finding Sources
Reading Article

PMID: 38987629

Reading File
Reading Article

PMID: 41445193

Reading File
Reading Article

PMID: 38697102

I now have substantial material from the textbook and the literature. Let me compile a comprehensive answer.

Gene Therapy in Cystic Fibrosis

Background: Why Gene Therapy?

Cystic fibrosis (CF) is caused by mutations in the CFTR gene, which encodes an epithelial chloride/bicarbonate channel. Over 2,000 mutations are known; the most common is F508del (a 3-nucleotide deletion causing protein misfolding). Without functional CFTR, the airway surface liquid dehydrates, mucociliary clearance fails, and thick mucus accumulates - leading to chronic infection, neutrophilic inflammation, and progressive structural lung damage.
CFTR modulators (ivacaftor, lumacaftor, tezacaftor, and the triple combination elexacaftor/tezacaftor/ivacaftor - Trikafta) have transformed CF management for the ~90% of patients with at least one F508del allele. However, roughly 10% of patients carry nonsense or null mutations that produce no CFTR protein at all, and therefore cannot respond to modulators. Gene therapy is the most viable disease-modifying strategy for this group - and potentially a one-time curative approach for all CF patients.

The Core Challenge: Delivering CFTR to the Airway

The CFTR gene (~6.2 kb coding sequence) is large. The target cells - airway basal stem cells - are particularly hard to transduce because:
  • They are covered by a thick mucus layer and a periciliary liquid layer
  • They sit beneath ciliated cells and express protective surface defenses
  • The airway is constantly exposed to inhaled particles and mounts rapid immune responses
  • Viral vector capacity is limited (esp. AAV, ~4.7 kb capacity)
As Plasschaert et al. (2024, Front Pharmacol, PMID 39439894) summarize: despite more than three decades of research, a lung-directed gene therapy has not yet been clinically realized - though the field is now advancing rapidly with new vector systems.

Approaches to CFTR Gene Therapy

1. Viral Vectors

Adenoviral vectors (AdV): First-generation adenoviral vectors could accommodate CFTR and showed transient expression in early trials (1990s). However, they triggered strong innate immune responses and did not integrate - expression was lost within weeks. High-capacity ("gutted") adenoviral vectors largely removed immunogenic viral genes but never reached the clinic for CF.
Adeno-associated virus (AAV): AAV is less immunogenic and gives more durable expression. The main limitation is payload: the standard CFTR cDNA (~4.7 kb) barely fits with essential regulatory elements. Truncated mini-genes (e.g., hCFTRΔR) have been used to compensate. SP-101 (Spirovant Sciences) is an AAV vector carrying a CFTR minigene (hCFTRΔR) being evaluated as an inhaled treatment.
Lentiviral vectors: Lentiviruses can carry larger payloads (~8 kb) and integrate stably into the host genome, allowing persistent expression in daughter cells after stem cell division. They have been tested in preclinical CF models and offer the theoretical advantage of life-long correction. Concerns include insertional mutagenesis (oncogenic risk), though modern self-inactivating (SIN) lentiviral designs have minimized this.
Sendai virus (SeV): An RNA virus with no risk of genomic integration; used in early-phase UK trials. Transient expression makes it suitable for proof-of-concept but limits durability.

2. Non-Viral Vectors

Cationic lipids / lipoplexes: The UK Cystic Fibrosis Gene Therapy Consortium conducted the first repeated-dose non-viral CFTR gene therapy trial using GL67A lipoplexes (nebulized). Their pivotal 2015 trial (Lancet Respir Med) showed modest but statistically significant stabilization of lung function (~3.7% FEV1 difference) in the treated group - proof of principle, but too small a benefit for clinical approval.
Lipid nanoparticles (LNPs): The most significant recent advance. LNPs are the same delivery technology used in COVID-19 mRNA vaccines, now adapted for inhaled pulmonary delivery of CFTR mRNA or CRISPR components.

mRNA Therapy: Providing a Template Instead of Editing DNA

Rather than permanently correcting the genome, CFTR mRNA therapy delivers synthetic mRNA encoding functional CFTR protein directly to airway cells. The protein is expressed transiently (days to weeks) but the therapy can be re-administered repeatedly.
Advantages:
  • Works regardless of mutation type (mutation-agnostic)
  • No risk of genomic integration or off-target DNA editing
  • The LNP delivery platform is clinically validated (COVID vaccines)
RCT2100 (ReCode Therapeutics): An inhaled CFTR mRNA therapy encapsulated in LNPs. As of November 2025, a Phase 2 trial (Part 3) has been granted FDA clearance and is enrolling in the US, UK, and EU. It is being co-administered with ivacaftor to evaluate safety and tolerability over 6 weeks. The Cystic Fibrosis Foundation invested an additional $3 million in this program in September 2025.
VX-522 (Vertex Pharmaceuticals): Vertex's investigational CFTR mRNA therapy, specifically targeting patients who produce no CFTR protein. This directly addresses the ~10% who cannot benefit from Trikafta.
LUNAR-CFTR (Arctus Biotherapeutics): A novel LNP system encapsulating codon-optimized CFTR mRNA. A 2026 study in Mol Ther showed that LUNAR-CFTR delivered to CF ferret airways restored CFTR-mediated ion transport to levels comparable to elexacaftor/tezacaftor/ivacaftor, and improved mucociliary clearance 3-fold with a single dose.

Gene Editing Approaches: Correcting the DNA Itself

Unlike gene addition (which delivers a copy alongside the faulty gene), editing directly repairs the mutant sequence.

CRISPR-Cas9

Standard CRISPR cuts both strands of DNA at the mutation site. A repair template (homology-directed repair, HDR) can then insert the corrected sequence. The challenge: HDR is efficient in dividing cells but poor in non-dividing airway epithelial cells, and the machinery (Cas9 + guide RNA + template) is large and difficult to deliver efficiently.

Prime Editing

Prime editing (PE) uses a CRISPR-derived "search and replace" mechanism without requiring double-strand DNA breaks, reducing off-target insertions/deletions. Two landmark studies in 2024-2025:
  • Bulcaen et al. 2024 (Cell Rep Med, PMID 38697102): Prime editing corrected L227R- and N1303K-CFTR (mutations ineligible for modulators) in patient-derived rectal organoids and nasal epithelial cells, with restored protein glycosylation, localization, and channel function.
  • Sousa et al. 2025 (Nat Biomed Eng, PMID 38987629): Systematic optimization of prime editing for F508del achieved 25% correction efficiency in patient-derived airway epithelial cells (up from <0.5% with baseline PE), restoring CFTR function to >50% of wild-type - comparable to triple modulator therapy. Off-target editing was minimal.

CRISPR + Full-Gene LNP Delivery (UCLA, 2026)

Researchers at UCLA (Foley RA et al., Adv Funct Mater, 2026) engineered LNPs carrying CRISPR/Cas9, guide RNAs, and a complete, full-length CFTR gene template for homology-directed repair - overcoming the "big gene problem." This non-viral system restored 88% of CFTR protein function in lab tests and is mutation-agnostic. As a platform, it may apply to other large-gene lung diseases.

Base Editing

Base editors convert individual DNA bases (e.g., C→T) without double-strand cuts. A 2023 Nat Commun study (PMID 38052872) demonstrated base editor delivery via shuttle peptides to rhesus monkey airway epithelia in vivo - an important step toward in vivo delivery of editors.

Key Challenges and Barriers

ChallengeDetails
Airway barrierMucus, periciliary layer, and tight junctions block vector access to basal stem cells
Immune responseRepeated dosing triggers innate/adaptive immunity, especially with viral vectors
Payload sizeCFTR cDNA is large; most viral vectors have size limits
Transient expressionmRNA and non-integrating vectors lose expression as airway cells turn over (~2-3 months)
Targeting stem cellsOnly correction of basal stem cells provides durable benefit; ciliated cells are short-lived
Clinical endpointsDetecting CFTR function with sufficient sensitivity in a heterogeneous population requires validated assays (nasal potential difference, intestinal current measurement, sweat chloride)
10% null-mutation patientsUnique target population with no alternative disease-modifying therapy

Clinical Trial Landscape (as of mid-2026)

AgentCompanyTypeStage
RCT2100ReCode TherapeuticsInhaled CFTR mRNA (LNP)Phase 2 (enrolling)
VX-522Vertex PharmaceuticalsInhaled CFTR mRNAPhase 1/2
SP-101Spirovant SciencesAAV (CFTR minigene, inhaled)Preclinical/early clinical
UCLA LNP-CRISPRUCLA / academicCRISPR + full CFTR (LNP)Preclinical (proof-of-concept)
Prime editingAcademic consortiaPE-F508del correctionPreclinical

Relation to CFTR Modulators

Gene therapy and modulators are not competing but complementary strategies. Modulators work only when defective CFTR protein is present; gene therapy/mRNA approaches work regardless of mutation. For the minority who cannot take modulators, gene therapy represents the primary route to disease modification. Even for patients on Trikafta, a one-time gene correction could eventually replace lifelong daily medication.
From Murray & Nadel's (Textbook of Respiratory Medicine): current CF treatment strategies "address downstream manifestations" of the ion channel defect, and the field increasingly views correction at the genetic level as the ultimate goal.

Summary

Gene therapy for CF has moved from early failed viral vector trials in the 1990s to a rapidly maturing field with multiple clinical programs. The shift to LNP-delivered mRNA (mutation-agnostic, repeatable, non-integrating) and precision genome editing (prime editing, base editing, CRISPR-guided full-gene insertion) represents the current frontier. The challenge of reaching and stably correcting airway basal stem cells remains the central biological barrier. With active Phase 2 trials (RCT2100, VX-522) and compelling preclinical data from prime editing and LNP-CRISPR systems, the field is closer to a clinically viable therapy than at any prior point - particularly for the ~10% of patients who have no current disease-modifying options.
Key recent references:
This is a shared conversation. Sign in to Orris to start your own chat.